Clinical Trials
47 trialsCEVOLUTION
Hoffmann-La Roche
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
MagnetisMM-6
Pfizer
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Canadian Cancer Trials Group
CARTITUDE-4
Janssen Research & Development, LLC
AURIGA
Janssen Research & Development, LLC
MajesTEC-3
Janssen Research & Development, LLC
A Study of Daratumumab
Janssen Research & Development, LLC
MajesTEC-7
Janssen Research & Development, LLC
iMMagine-3
Gilead Sciences
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
MAGNETISMM-5
Pfizer
DURGA-4
AstraZeneca
DREAMM 7
GlaxoSmithKline
DREAMM 7
GlaxoSmithKline
DREAMM 7
GlaxoSmithKline
DREAMM-10
GlaxoSmithKline
MonumenTAL-3
Janssen Research & Development, LLC
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
EXCALIBER-RRMM
Celgene
ElLen
Intergroupe Francophone du Myelome
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
CARTITUDE-6
European Myeloma Network B.V.
LINKER-SMM2
Regeneron Pharmaceuticals
Perseus
European Myeloma Network B.V.
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
EMN14
European Myeloma Network B.V.
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
DRAMMATIC
SWOG Cancer Research Network
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
FUMANBA-03
Nanjing IASO Biotechnology Co., Ltd.
RADIA
The First People's Hospital of Changzhou
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
CANDOR
Amgen
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Cassiopeia
Intergroupe Francophone du Myelome
CONFIRM
Assistance Publique - HĂ´pitaux de Paris
HOVON174MM
Stichting Hemato-Oncologie voor Volwassenen Nederland
ALUMMINATE
Celgene
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
DARVIVA
Biocad
LIGHTHOUSE
Oncopeptides AB
KarMMa-3
Celgene